Inhibikase Therapeutics, Inc. · NASDAQ:IKT
Inhibikase Therapeutics — Investor Presentation (April 2024)
25 slides from Inhibikase Therapeutics's investor presentation, Apr 30, 2024
Slide 1: 2Q24 Business Presentation
Exhibit 99.1 2Q24 | BUSINESS PRESENTATION Clinical Development of Disease-Modifying Therapeutics for Neurodegenerative Disease, Cancer and Cardiopulmonary Disease Inhibikase.com : IKT
Slide 2: Disclaimer
DISCLAIMER This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification unde
Slide 3: Offering Summary
OFFERING SUMMARY Inhibikase Therapeutics, Inc. (“IKT” or the “Company”) ISSUER: Nasdaq Capital Market: IKT EXCHANGE/SYMBOL: Best Efforts S-1 Follow-on OFFERING TYPE: Up to $13.0 Million GROSS PROCEEDS: Units consisting of one share of Common Stock (or one Pre-Funded Warrant in lieu SECURITIES TO BE
Slide 4: Multi-Therapeutic Pipeline of Kinase Inhibitor Therapeutics
MULTI-THERAPEUTIC PIPELINE OF KINASE INHIBITOR THERAPEUTICS Developing innovative medicines across the therapeutic spectrum • Multi-therapeutic pipeline across neurodegenerative disease, cancer and cardiopulmonary disease • Risvodetinib (IkT-148009): Selective c-Abl inhibitor. Phase 2 ongoing to eva
Slide 5: Company Highlights: Multi-Therapeutic Pipeline
COMPANY HIGHLIGHTS: MULTI-THERAPEUTIC PIPELINE Multi-Indication Pipeline in Neurodegeneration, Oncology and Non-oncology Indications 1 CLINICAL DEVELOPMENT (1). ‘Clinical Development’ progress PRECLINICAL bars represent the current state of the DRUG TARGET DRUG CANDIDATE MODALITY DISEASE INDICATION
Slide 6: Parkinson's Disease Market & Strategy
Parkinson’s and Related Disorders Parkinson’s Disease Market & Strategy Inhibikase.com • : IKT 6
Slide 7: The Market: Disease-Modification Will Transform Treatment Paradigm
THE MARKET: DISEASE-MODIFICATION WILL TRANSFORM TREATMENT PARADIGM 1 Parkinson’s disease and MSA in the U.S. Parkinson’s: Slowly Progressing MSA: Rapidly Progressing 1/3 of a Patient’s Lifespan to death = 25 years 1/10 of a Patient’s Lifespan to death = 8 years Global treatment sales for PD by 2030
Slide 8: Searching for the Role of the Misfolded Protein in Major CNS Disease
1 SEARCHING FOR THE ROLE OF THE MISFOLDED PROTEIN IN MAJOR CNS DISEASE Different proteins, similar pathological effect b-amyloid and Tau in Alzheimer’s a-synuclein in PD, MSA, DLB What role does the misfolded protein play? 1 Nat. Neurosci. 21: 1332-1340 (2018) Inhibikase.com • : IKT 8
Slide 9: External or Internal as a Site of Targeting?
EXTERNAL OR INTERNAL AS A SITE OF TARGETING? antibody or Clearance of pathological plaque unknown dis-aggregator targets plaque NOT restorative outside affected neurons mechanistic inhibitors Does clear pathological plaques like risvodetinib CAN BE restorative target plaque inside affected neurons 1
Slide 10: Risvodetinib Modifies Parkinson's Disease
RISVODETINIB MODIFIES PARKINSON'S DISEASE c-Abl inhibition by Risvodetinib restores lost function in Validated Animal 1 Models of Parkinson’s disease a Neurodegeneration Motor Dysfunction -Synuclein Toxicity Neuroinflammation preserves restores clears suppresses as much as 85% as much as 90% to base
Slide 11: The Trial evaluating Risvodetinib in Untreated Parkinson's Disease
The 201 Trial evaluating Risvodetinib in Untreated Parkinson’s Disease Inhibikase.com • : IKT 11
Slide 12: Trial Design and Patient Flow
The 201 TRIAL: TRIAL DESIGN AND PATIENT FLOW or 92 As of April 23, 2024 or Inhibikase.com • : IKT 12
Slide 13: Possibly Risvodetinib-Related Adverse Events as of April 23, 2024
THE 201 TRIAL; POSSIBLY RISVODETINIB-RELATED ADVERSE EVENTS AS OF APRIL 23, 2024 Adverse Event Severity (# Occurrences) Gastrointestinal Nausea (1) Mild Vomiting (3) Mild (3) 25 AEs occurred in 17 of Gas/Cramps (2) Mild (1)/Moderate (1) 92 enrolled participants Heartburn (1) Mild Diarrhea (3) Mild C
Slide 14: Trial: Early Unblinded Observations
201 TRIAL: EARLY UNBLINDED OBSERVATIONS Functional Assessment: Universal Parkinson’s Disease Rating Scale (MDS-UPDRS) Part 2: Measures ability to do everyday activities (teeth brushing, dressing on your own, etc.) Part 3: Measures ability to do walk, stand, balance Improvement occurs when numbers de
Slide 15: The Trial; Biomarker Analysis Ongoing
THE 201 TRIAL; BIOMARKER ANALYSIS ONGOING Blood and CSF biomarkers Tissue-derived biomarkers Tissue biomarkers may indicate clearance of plaque Spinal fluid biomarkers may confirm proper diagnosis of pathology in the 201 Trial. Proprietary antibody against disease in the 201 Trial. phosphorylated al
Slide 16: Inhibition of c-Abl May Have a Wider Role in Other Diseases
INHIBITION OF C-Abl MAY HAVE A WIDER ROLE IN OTHER DISEASES Risvodetinib in other neurodegenerative disease 1 MSA ALS Alzheimer’s J Neurol Sci. 2018;393:80-82 Prog Neurobiol. 2021;202:102031 Autophagy. 2021;17(5):1278-1280. Sci Transl Med. 2017;9(391):eaaf3962 J Biol Chem. 2020 ;295(23):7905-7922 Fr
Slide 17: IkT-001Pro for Treatment of Blood and Stomach Cancers and Cardiopulmonary Disease
IkT-001Pro for Treatment of Blood and Stomach Cancers and Cardiopulmonary Disease Inhibikase.com • : IKT 17
Slide 18: IkT-001Pro Innovation
IkT- 001Pro INNOVATION IkT-001Pro releases the active ingredient imatinib only in blood 4-carbon atom linker imatinib linker gut wall + pH 2-6 pH 7 (blood) (stomach, ileum, duodenum) Lifetime in blood < 10 min Inhibikase.com • : IKT 18
Slide 19: IkT-001Pro Is a Small Molecule c-Abl Inhibitor
IkT- 001Pro IS A SMALL MOLECULE C-Abl INHIBITOR IkT-001Pro has less toxicity in non-human primate: Potentially Safer Alternative to Imatinib Mesylate Measurement of IkT-001Pro in Non-Human Primates RESULTS SUGGEST THAT: No Adverse Event Level Cmax Tmax AUC 0-T (mg/kg) ü Achieve dose flexibility, (me
Slide 20: Trials in Bioequivalence and Superiority: IkT-001Pro Summary
TRIALS IN BIOEQUIVALENCE AND SUPERIORITY Clinical Development of IkT-001Pro: Summary § Phase 3 Complete in Blood and Stomach Cancers Ø Competes against generic imatinib mesylate 1 Ø≈$300M market US § Phase 2/3 Ready in Pulmonary Arterial Hypertension Ø Proven to be disease-modifying, but Phase 3 nee
Slide 21: Selected Financial Data
Selected Financial Data IIn nh hib ibik ika as se e..c co om m • • :: IK IKT T 21 21
Slide 22: Selected Financial and Stock Data
COMPANY HIGHLIGHTS Selected Financial and Stock Data Capitalization Table April 15, 2024 Balance Sheet December 31, 2023 Common Shares Outstanding 6,476,844 Current Assets: Options (WAEP: $10.33) 985,280 Cash, Cash Equivalents, Warrants (WAEP: $7.64) 2,266,136 $13,252,052 Marketable Securities Prepa
Slide 23: About Us / Executives
ABOUT US / EXECUTIVES Management Team with Deep Experience in Drug Development and Commercialization Milton Werner, PhD Garth Lees-Rolfe C. Warren Olanow, MD, President & CEO Chief Financial Officer Medical Consultant and Chief Executive Officer of Clintrex Research Corporation. Previously, Dr. Wern
Slide 24: About Us / Board of Directors
ABOUT US / BOARD OF DIRECTORS Mr. Dennis Berman Ms. Gisele Dion Dr. Roy Freeman, MD Dr. Paul Grint, MD • Co-founder, board member, and/or • Chief Accounting Officer of Alnylam • Professor of Neurology at the Harvard • 20+ years experience in biologics and seed investor in many private Pharmaceutical
Slide 25: About Us / Industry-Leading Advisors
ABOUT US / INDUSTRY-LEADING ADVISORS Dr. Valina Dawson, PhD Dr. Karl Kieburtz, MD, MPH Dr. Robert Hauser, MD Neurodegeneration and Stem Cell Programs, Institute for Cell Robert J. Joynt Professor in Neurology, Senior Associate Dean for Professor of Neurology, University of Engineering, Departments o
Inhibikase Therapeutics — Investor Presentation (April 2024) on 6ix